Nuvig Therapeutics raised $161 million in a Series B funding round co-led by Sanofi Ventures and Blue Owl Healthcare Opportunities to support the clinical development of its novel immunomodulatory therapeutics.
Global BioAccess FundMission BioCapitalLeaps By BayerLotte HoldingsAlexandria Venture InvestmentsAbrdn Inc.Novo Holdings A/SPlatanusGlobal Bio Access FundNorwest Venture PartnersB CapitalBristol Myers SquibbDigitalis VenturesMission Bio CapitalSanofi VenturesBlue Owl Healthcare Opportunities
Description
Nuvig Therapeutics announced the closing of a $161 million Series B financing to advance its novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases. The financing will support clinical proof-of-concept studies for lead candidate NVG-2089 and the company's preclinical pipeline.
Company Information
Company
Nuvig Therapeutics
Location
4200 Bohannon Dr
Menlo Park, California, United States
About
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.
Fundz sees it the moment Nuvig Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Menlo ParkBiotechnologyHealth CareTherapeuticsresearch